"Bureaucratic" Zoon leaves CBER (Center for Biologics Evaluation and Research) to return to NIH (National Institutes of Health)
This article was originally published in Clinica
Virologist Jesse Goodman has been named to replace Kathryn Zoon as director of US FDA's Center for Biologics Evaluation and Research (CBER). Dr Zoon, who announced her resignation on December 13, said she was driven away in part by the agency's recent decision to shift authority for therapeutic biologics to the FDA's drug centre.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.